Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 36,601 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total transaction of $2,274,752.15. Following the sale, the chief executive officer directly owned 430,330 shares in the company, valued at $26,745,009.50. The trade was a 7.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Cytokinetics Trading Up 0.1%

CYTK traded up $0.06 during midday trading on Wednesday, reaching $62.19. The company’s stock had a trading volume of 1,983,803 shares, compared to its average volume of 1,895,650. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $70.98. The stock’s 50-day moving average is $63.86 and its 200-day moving average is $60.93. The firm has a market capitalization of $7.66 billion, a price-to-earnings ratio of -9.52 and a beta of 0.56.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million for the quarter, compared to analysts’ expectations of $8.02 million. During the same period last year, the firm earned ($1.26) EPS. The business’s revenue was up 4.9% on a year-over-year basis. As a group, equities research analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CYTK. Jefferies Financial Group reissued a “buy” rating and issued a $90.00 target price on shares of Cytokinetics in a research note on Friday, January 9th. JPMorgan Chase & Co. lifted their price target on Cytokinetics from $74.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday. HC Wainwright upped their price target on shares of Cytokinetics from $120.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research report on Monday, December 22nd. Finally, UBS Group raised their price objective on shares of Cytokinetics from $61.00 to $69.00 and gave the company a “neutral” rating in a research note on Friday, March 6th. Seventeen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $89.89.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Woodline Partners LP raised its position in Cytokinetics by 676.1% in the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock worth $90,559,000 after buying an additional 1,435,422 shares during the last quarter. Norges Bank purchased a new stake in shares of Cytokinetics during the 2nd quarter valued at about $39,122,000. Deep Track Capital LP grew its stake in shares of Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after acquiring an additional 650,000 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in shares of Cytokinetics by 151,987.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock worth $35,949,000 after acquiring an additional 565,393 shares during the period. Finally, Frazier Life Sciences Management L.P. purchased a new position in shares of Cytokinetics during the second quarter valued at approximately $18,328,000.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Mizuho raised its price target on CYTK to $100 and kept an outperform rating, signaling strong upside versus the current price and supporting bullish investor expectations. Mizuho raises PT to $100
• Positive Sentiment: JPMorgan nudged its target up from $74 to $75 and maintains an overweight/positive stance, reinforcing the buy-side view. JPMorgan raises PT to $75
• Positive Sentiment: Barclays reiterated a Buy rating on CYTK, adding to a broad base of favorable analyst coverage and a consensus price-target materially above the current level. Barclays keeps Buy rating
• Neutral Sentiment: Cytokinetics granted options (8,628 shares) and 5,719 RSUs as inducements to five new hires — standard hiring compensation but modestly dilutive over time. Inducement grants announcement
• Neutral Sentiment: Coverage and valuation pieces (including assessments after MYQORZO trial data) keep attention on the drug pipeline; results and safety updates will remain key catalysts. MYQORZO valuation assessment
• Negative Sentiment: Significant insider selling: CEO Robert Blum sold 36,601 shares (~$2.27M at ~\$62.15). Large insider disposals can signal liquidity needs or rebalancing and may pressure sentiment. CEO Form 4
• Negative Sentiment: Other senior executives sold notable blocks this week (EVP Fady I. Malik: 12,033 shares; EVP Andrew Callos: multiple sales including 1,930 and earlier lots; EVP Sung Lee: 4,935 shares), representing single-digit percentage ownership reductions—adds to selling narrative. EVP Form 4s

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.